Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
NYSE MKT:PHGE
Holding PHGE?
Track your performance easily
PHGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.56 - $8.56
Previous Close$0.58
Volume103.80K
Average Volume (3M)92.69K
Market Cap
$10.54M
Enterprise Value-$3.25M
Total Cash (Recent Filing)$23.54M
Total Debt (Recent Filing)$9.75M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Mar 26, 2025EPS Estimate
-$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.35
Shares Outstanding18,176,602
10 Day Avg. Volume68,446
30 Day Avg. Volume92,695
Standard Deviation0.27
R-Squared0.06
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$2.00Price Target Upside292.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BiomX News
PremiumCompany Announcements
BiomX Inc. Reports Q3 2024 Financial Turnaround
PremiumCompany Announcements
BiomX Shares Phage Therapy Advances and Vision
Bulls Say, Bears Say
Bulls Say
Acquisition And Pipeline ExpansionThe recent merger with Adaptive Phage Therapy expanded BiomX’s pipeline with the addition of BX211.
Clinical Trial SuccessThe company announced positive safety and efficacy results from its Phase 1b/2a trial evaluating BX004 in chronic pulmonary infections.
Financial PerformanceBiomX announced 3Q24 financial results, posting EPS of $0.31 compared with an estimate of ($0.06).
Bears Say
Healthcare RisksDiabetic foot osteomyelitis is identified as a frequent and serious complication for individuals with diabetes.
Market ChallengesCurrent treatment options for diabetic foot osteomyelitis range from insufficient to maximal interventions, such as surgery, amputation, and antibiotics.
Product DevelopmentManufacturing delays have pushed the expected topline data from the BX004 study to be released by 1H26.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.56 and its highest was $8.56 in the past 12 months.
What is BiomX’s market cap?
Currently, no data Available
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on Nov 14, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.19.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -$1.1.
How many shares outstanding does BiomX have?
BiomX has 18,176,601 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of BiomX?
Among the largest hedge funds holding BiomX’s share is Deerfield Management Company, LP. It holds BiomX’s shares valued at 623K.
---
BiomX Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (292.93% Upside)
$2.00 (292.93% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.87%
12-Months-Change
Fundamentals
Return on Equity
-72.95%
Trailing 12-Months
Asset Growth
81.45%
Trailing 12-Months
Company Description
BiomX
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
---
PHGE Earnings Call
Q3 2024
0:00 / 0:00
---
PHGE Stock 12 Month Forecast
Average Price Target
$2.00
▲(292.93% Upside)
Technical Analysis
Best Analysts Covering PHGE
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-52.45%
reiterated a buy rating 3 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -52.45% per trade.
---